Tetrac

SKU: orb1693507

Description

Tetrac is a thyroid hormone derivative that acts as an antagonist at the cell-surface integrin αvβ3 receptor, blocking pro-angiogenic and proliferative signals from T4, T3, and EGFR. This mechanism underpins its studied anti-tumor and pro-apoptotic activities in colorectal cancer models, supporting its use in oncology and angiogenesis research.

Research Area

Cardiovascular Research, Cell Biology, Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 67-30-1
• MW: 747.83
• Purity: 99.04%
• Formula: C₁₄H₈I₄O₄
• SMILES: OC(=O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1
• Target: EGFR,Apoptosis,Endogenous Metabolite,Integrin
• Solubility: DMSO:45 mg/mL (60.17 mM)

Bioactivity

• In Vivo:
  Tetrac (35 μg/day; p.o.; for 40 days; Wild-type male Balb/C mice inoculated with 102B16F10 or B16LS9 cells) delayed the onset of ocular melanoma and reduced the S-100 and integrin staining levels. Tetrac can inhibit tumor inoculation, growth, and integrin expression in mice.
• In Vitro:
  Tetrac (0.01-1 μM; 2-6 d) induces anti-proliferation in HT-29 and HCT116 cells with different K-RAS status, inhibits ERK1/2 activation (0.1 μM; 30 min), and modulates expression of CCND1, c-Myc, CASP2, and THBS1 (0.1 μM; 24 h), as demonstrated by cell proliferation assays in HT-29 and HCT116 cells.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Apoptosis, 3,3',5,5'-Tetraiodothyroacetic acid, EGFR, Tetrac, Tetraiodothyroacetic acid, thyroxine

Compound Identifiers

PubChem CID

65552